Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Up 15.4% in August

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXGet Free Report) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 33,800 shares, an increase of 15.4% from the August 15th total of 29,300 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 961,300 shares, the short-interest ratio is presently 0.0 days.

Eloxx Pharmaceuticals Price Performance

Shares of NASDAQ:ELOX traded up $0.09 during midday trading on Tuesday, reaching $5.55. The company’s stock had a trading volume of 20,836 shares, compared to its average volume of 564,148. The business’s fifty day simple moving average is $5.89 and its 200-day simple moving average is $5.60. Eloxx Pharmaceuticals has a fifty-two week low of $1.70 and a fifty-two week high of $10.90. The company has a market capitalization of $15.26 million, a P/E ratio of -0.48 and a beta of 2.66.

Eloxx Pharmaceuticals (NASDAQ:ELOXGet Free Report) last issued its quarterly earnings results on Monday, August 14th. The company reported ($1.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.42). On average, analysts forecast that Eloxx Pharmaceuticals will post -7.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eloxx Pharmaceuticals

A hedge fund recently bought a new stake in Eloxx Pharmaceuticals stock. Renaissance Technologies LLC acquired a new position in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOXFree Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 179,400 shares of the company’s stock, valued at approximately $48,000. Renaissance Technologies LLC owned 0.21% of Eloxx Pharmaceuticals at the end of the most recent quarter. Institutional investors own 8.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer lifted their price target on Eloxx Pharmaceuticals from $50.00 to $55.00 in a research report on Tuesday, July 11th.

Read Our Latest Research Report on ELOX

Eloxx Pharmaceuticals Company Profile

(Get Free Report)

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.

See Also

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.